CD274 and non-small cell lung carcinoma: IHC based assays remain important tests as companion diagnostics (CDx) to assess antigen expression on diagnostic or surgical specimens for selecting patients and predicting patient-response to specific targeted therapies (e.g., HER2 expression for Herceptin), and more recently PD-L1 measurement as a CDx for pembrolizumab treatment of NSCLC patients.